Evaluation of serum biomarkers for detection of preeclampsia severity in pregnant women

Maryam Kasraeian1, Nasrin Asadi2, Homeira Vafaei3, Tarlan Zamanpour4, Hadi Raesi Shahraki5, Khadije Bazrafshan6

ABSTRACT

Objectives: To determine serum biomarkers in detection of preeclampsia severity among pregnant women.

Methods: Among 450 pregnant women with various severity of preeclampsia, serum biomarkers of aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), hemoglobin (Hb), platelet count (PLT), uric acid, direct bilirubin, total bilirubin, creatinine, and alkaline phosphatase were compared using area under the Receiver operating characteristic (ROC) curve and Area Under the Curve (AUC).

Results: The mean age of women was 30.63±6.43 years and with mean gestational age of 34.69±3.97 weeks. The mean level of LDH, ALT, uric acid, and creatinine were significantly higher in the women with severe type of preeclampsia compared to those with mild type. LDH level had ROC and AUC of more than 0.80, with highest sensitivity, and moderate specificity in comparison to other markers.

Conclusion: Biomarkers such as ALT, uric acid, and LDH were shown to be prognostic in detection of the severity of preeclampsia. LDH was demonstrated to significantly be a better prognostic test in detection of preeclampsia severity.

KEY WORDS: Biomarker, Preeclampsia, Pregnancy, Severity.

INTRODUCTION

One of the important conditions in pregnant women is hypertensive disorder with serious maternal and fetal complications.1 Among hypertensive disorders, preeclampsia is one of the most important life threatening one for both mothers and neonates worldwide, with 10–15% of the 500,000 maternal deaths each year.2,3 Routine investigation of women with preeclampsia includes determination of liver function test (LFT) including aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), bilirubin, and albumin levels. There are controversies for association between these parameters and severity of preeclampsia in literature.4

Mean arterial blood pressure, uterine vessels ultrasound,5 serum calcium level6, serum uric acid level,6,7 LDH,7 angiogenesis factors such as placental growth factor (PIGF) and vascular endothelial growth factor (VEGF),8 lipid profile,9 and glucose
tolerance test were previously studied to evaluate the association between these parameters and severity of preeclampsia. In UK, several guidelines were presented for early diagnosis based on assessment of maternal risk factors; including a screening strategy based on maternal history and characteristics by the National Institute of Clinical Excellence (NICE) predicting less than 30% of those developing preeclampsia. So there is serious need to assess this association. The present study was undertaken to compare serum biomarkers in pregnant women with different severities of preeclampsia as prognostic ones in maternal and fetal outcomes.

METHODS

This retrospective study included 450 women with preeclampsia who were referred to Hafez Hospital affiliated to Shiraz University of Medical Sciences from 2005 to 2014. The study was approved by the local Institutional Ethics Review Board (EC-P-9382-8682 dated Feb. 13, 2014). The inclusion criteria for the women with mild preeclampsia were (i) Systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg and (ii) Proteinuria ≥0.3 grams in 24-hour urine specimen.

The inclusion criteria for the women with severe preeclampsia were:
1. Signs of liver problems (such as vomiting with abdominal pain)
2. Signs of central nervous system problems (such as blurry vision and severe headache)
3. Very high blood pressure (greater than 160 systolic or 110 diastolic)
4. At least twice the normal measurements of certain liver enzymes on blood test
5. Thrombocytopenia
6. Greater than 5g of protein in a 24-hour sample
7. Very low urine output (less than 500mL in 24 hours)
8. Signs of respiratory problems (such as pulmonary edema)
9. Severe fetal growth restriction
10. Stroke

The women with unstable conditions were excluded from the study. Information such as age, gestational age (GA), and serum levels of LDH, hemoglobin (Hb), platelet count (PLT), uric acid, direct bilirubin, total bilirubin, AST, ALT, serum creatinine (Scr), and alkaline phosphatase, were compared between the women with mild and severe preeclampsia. The obtained data were reported as mean±SD. SPSS software (Version 20, Chicago, IL, USA) was used for statistical analysis. Independent T-test, Pearson’s chi-square and Fisher’s exact tests were used to compare the groups. Receiver Operating Characteristic (ROC) curve was drawn to specify the optimal cut-off points of the variables for prediction of preeclampsia. Sensitivity, specificity, and the Areas Under the Curves (AUC) were also calculated with 95% confidence intervals. A P-value<0.05 was considered as statistically significant.

RESULTS

Out of the 450 women, 180 and 270 ones were assigned to the mild and severe preeclampsia groups, respectively. Among the 450 births, 221 neonates were male, 217 were female, and 12 were twin male-female neonates. The mean age of pregnant women was 30.63±6.43 years with the mean GA of 34.69±3.97 weeks. Out of the 12 women with twin pregnancies, 11 (91.67%) showed severe preeclampsia (P=0.03). No significant association was noted between the neonates’ sex and severity of preeclampsia (P=0.49). The comparison of serum biomarkers in pregnant women with mild and severe preeclampsia was presented in Table-I. The two groups were significantly different for GA, LDH, PLT, uric acid, ALT, and Scr. The mean GA of women with mild preeclampsia was higher compared to those with severe preeclampsia (P<0.001). The mean level of PLT was also higher among the mild cases of preeclampsia in comparison to severe cases.

Fig.1: Receiver operating characteristic (ROC) curve for lactate dehydrogenase (LDH).
Serum biomarkers in preeclampsia

Findings for variables with higher AUC are presented in Table-II, but for variables with AUC<0.6 were not shown. The LDH level had ROC and AUC >0.80, with the highest sensitivity, and moderate specificity in comparison to other tests. ALT, AST, and uric acid denoted to a moderate sensitivity and specificity, while SCr had the highest specificity and the lowest sensitivity among the variables (Table-II).

DISCUSSION

Maternal complications, such as proteinuria, eclampsia, severe hypertension, hemolysis, abnormal LFTs, and low platelet count can result from preeclampsia. Some biomarkers have also been reported to be significantly associated with preeclampsia during pregnancy. Martin et al. proposed a protocol for quick hazard assessment of severe preeclampsia shortly after meeting study admission criteria evaluating symptoms and levels of AST, ALT, LDH, uric acid, proteinuria, and creatinine. The differences in SCr level between the normal pregnant women and those suffering from preeclampsia were shown not to be significant.

Our results were in line with the study presented an increased level of SCr in preeclampsia women compared to those with normal pregnancy. Our findings revealed that SCr test was poorly sensitive and had the lowest predictive value to differentiate the severity of preeclampsia. Uric acid level, as a marker of oxidative stress, tissue injury, and renal dysfunction, is increased in hypoxia and ischemia of the placenta. Thus, measuring serum uric acid may be used to predict preeclampsia and the mean level of uric acid can be associated with the severity of preeclampsia.

Alavi et al. found a significant difference for serum calcium and uric acid between the normal pregnant women and those with signs of preeclampsia. In 2009, serum uric acid was found to predict maternal complications in management of preeclampsia under realistic assumptions. It was demonstrated that preeclamptic patients with increased serum uric acid values had to undergo induced labor due to their increased risk of complications.

Table-I: Paraclinical parameters of the pregnant women with severe and mild preeclampsia.

| Parameter | Severity of preeclampsia | Mean±SE | P-value† |
|-----------|--------------------------|---------|----------|
| Age (year) | Mild | 30.16±5.96 | 0.24 |
| | Severe | 30.89±6.76 | |
| GA (month) | Mild | 37.73±2.27 | <0.001 |
| | Severe | 32.67±3.52 | |
| LDH (IU/L) | Mild | 337.89±173.15 | <0.001 |
| | Severe | 556.41±193.02 | |
| Hb (g/dL) | Mild | 11.8±1.62 | 0.89 |
| | Severe | 11.78±1.8 | |
| PLT (×10⁹.L⁻¹) | Mild | 191.18±49.06 | 0.019 |
| | Severe | 179.08±56.35 | |
| Uric acid (mg/dL) | Mild | 5.43±1.2 | <0.001 |
| | Severe | 6.2±1.4 | |
| Direct bilirubin (mg/dL) | Mild | 0.23±0.08 | 0.415 |
| | Severe | 0.24±0.09 | |
| Total bilirubin (mg/dL) | Mild | 0.6±0.22 | 0.86 |
| | Severe | 0.6±0.18 | |
| ALT (IU/L) | Mild | 18.78±30.38 | 0.001 |
| | Severe | 32.99±54.07 | |
| AST (IU/L) | Mild | 32.45±50.8 | 0.07 |
| | Severe | 43.54±73.63 | |
| SCr (mg/dL) | Mild | 0.84±0.27 | 0.017 |
| | Severe | 0.9±0.26 | |
| Alkaline phosphatase (IU/L) | Mild | 333.94±120.61 | 0.35 |
| | Severe | 321.42±147.74 | |

†: Independent T-test, ALT: alanine transaminase, AST: aspartate transaminase, SCr: serum creatinine, GA: gestational age, Hb: hemoglobin, LDH: lactate dehydrogenase, PLT: platelet count, SE: standard error.

to those with severe preeclampsia (P=0.019). The mean level of LDH, ALT, uric acid, and SCr were significantly higher in the women with severe type preeclampsia compared to those with mild type.

The ROC curve for LDH is shown in Fig.1. Findings for variables with higher AUC are presented in Table-II, but for variables with AUC<0.6 were not shown. The LDH level had ROC and AUC >0.80, with the highest sensitivity, and moderate specificity in comparison to other tests. ALT, AST, and uric acid denoted to a moderate sensitivity and specificity, while SCr had the highest specificity and the lowest sensitivity among the variables (Table-II).

Table-II: The variables with high area under curve (AUC). The data are presented as point estimation with 95% confidence interval.

| Paraclinical parameters | AUC | Cut-off point | Sensitivity | Specificity |
|-------------------------|-----|---------------|-------------|-------------|
| LDH                    | 0.805 (0.765-0.842) | 336 | 89.62 (86.22-93.02) | 59.3 (51.6-66.7) |
| Uric acid              | 0.666 (0.618-0.712) | 5.53 | 68.67 (62.5-74.4) | 58.54 (50.6-66.2) |
| ALT                    | 0.657 (0.609-0.702) | 14.33 | 62.16 (56-68.1) | 62.73 (54.8-70.2) |
| AST                    | 0.604 (0.556-0.651) | 0.25 | 57.92 (51.6-64) | 60.49 (52.5-68.1) |
| SCr                    | 0.604 (0.555-0.652) | 0.96 | 29.64 (24.1-35.7) | 89.1 (83.1-93.5) |

ALT: alanine transaminase, AST: aspartate transaminase, SCr: serum creatinine, LDH: lactate dehydrogenase.
our results showed a higher mean level of maternal serum uric acid in women with severe preeclampsia in comparison to those with mild type (P<0.001).

Although the mean level of uric acid was higher in preeclampsia pregnant in comparison to women with normal pregnancy, uric acid level cannot be used as a suitable index for management of preeclampsia. The mean increase in uric acid level was variable in preeclampsia patients in different areas that can explain the difference. The diversity in areas, diets, nutrition, and breeds of preeclampsia subjects can be other contributing factors. Burwick and Feinberg (2013) found a considerable increase in liver enzymes in patients with preeclampsia and showed that high levels of AST and ALT can be considered to categorize the severity of preeclampsia.

Kozic JR et al. in 2008 women with preeclampsia investigated LFT results to predict adverse maternal outcomes and demonstrated that 53% of patients had at least one abnormality in LFT levels denoting an increased risk of adverse maternal outcomes. In a systematic review article, Thangaratinam S et al. investigated the accuracy of LFT for predicting adverse maternal and fetal outcomes in women with preeclampsia as the best moderate predictors of maternal and fetal complications in women with preeclampsia. ALT level was significantly higher in the severe cases of preeclampsia compared to the mild ones. Similar to the study by Thangaratinam et al., our results revealed a moderate sensitivity and specificity for LFT in differentiation of preeclampsia severity.

Demir SC et al. indicated a statistically significant relationship between maternal complications and high LDH levels. Moreover, Odendaal HJ et al. presented that LDH level before delivery was significantly higher in early onset of severe preeclampsia. Jaiswar et al. showed that LDH level significantly elevated in women with preeclampsia and eclampsia. They reported that high serum LDH level had a correlation for severity of the disease and poor outcomes in patients with preeclampsia and eclampsia. In the same line, Qublan et al. revealed that the mean LDH level was 348±76 IU/l in patients with mild preeclampsia and 774±69.61 IU/l in those with severe preeclampsia. They also found a significant association between serum LDH level and severity of preeclampsia. In the present study, the mean LDH level was 337.89±173.15IU/l and 556.41±193.02IU/l in patients with mild and severe preeclampsia, respectively.

Kozic et al. displayed that LDH level had ROC and AUC > 0.70 and were modestly predictive tests to show adverse maternal outcomes in women with preeclampsia. In agreement with Kozic et al., our finding demonstrated that LDH level had ROC and AUC > 0.80, with the highest sensitivity, and moderate specificity in comparison to other tests. The study by Peralta et al. showed a significant difference between the mild and severe preeclampsia patients and healthy controls regarding LDH level too. In the present study, LDH levels significantly raised based on the severity of the disease (P<0.001).

Limitations of the study: It included lack of a normal and healthy control group and lack of attention to the patients’ trimester of pregnancy as there are different strategies in prediction of preeclampsia in each trimester.

CONCLUSION

We can conclude that ALT, uric acid, and LDH levels can be predictive factors in identification and categorization of the severity of preeclampsia in pregnant women, even LDH level had the highest sensitivity and moderate specificity in comparison to other parameters.

ACKNOWLEDGMENTS

The authors are grateful to Shiraz University of Medical Sciences for financial support. The authors are also grateful to Mohsen Varzande for editing and improving English language in the manuscript.

Conflict of Interest: The authors declare that they have no competing interest.

REFERENCES

1. Hu WS, Feng Y, Dong MY, He J. Comparing maternal and perinatal outcomes in pregnancies complicated by preeclampsia superimposed chronic hypertension and preeclampsia alone. Clin Exp Obstet Gynecol. 2016;43:212-215.
2. Kar M. Role of biomarkers in early detection of preeclampsia. J Clin Diagn Res. 2014;8:BE01-BE04. doi: 10.7860/jcdr/2014/7969.4261.
3. Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367:1066-1074. doi: 10.1016/S0140-6736(06)68397-9.
4. Kozic JR, Benton SJ, Hutcheon JA, Payne BA, Magee LA, von Dadelszen P, et al. Abnormal liver function tests as predictors of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can. 2011;33:995-1004. doi: 10.1016/s1701-2163(16)35048-4.
5. Baschat AA, Magder LS, Doyle LE, Atlas RO, Jenkins CB, Blitzer MG. Prediction of preeclampsia utilizing the first trimester screening examination. Am J Obstet Gynecol. 2014;211:514 e1-7. doi: 10.1016/j.ajog.2014.04.018.
Serum biomarkers in preeclampsia

6. Alavi A, Jahanshahi K, Karimia S, Arabzadea N, Fallahi S. Comparison of serum calcium, total protein and uric acid levels between hypertensive and healthy pregnant women in an Iranian population. Life Sci J. 2012;9:485-488.

7. Jaiswar SP, Gupta A, Sachan R, Natu SN, Shalih M. Lactic dehydrogenase: a biochemical marker for preeclampsia eclampsia. J Obstet Gynaecol India. 2011;61:645-648. doi: 10.1007/s13224-011-0093-9.

8. Di Lorenzo G, Ceccarello M, Cecotti V, Ronfani L, Monasta L, Vecchi Brumatti L, et al. First trimester maternal serum PIGF, free beta-hCG, PAPP-A, PP-13, uterine artery Doppler and maternal history for the prediction of preeclampsia. Placenta. 2012;33:495-501. doi: 10.1016/j.placenta.2012.03.003.

9. Parra-Cordero M, Sepulveda-Martinez A, Preslier J, Pasten J, Soto-Chacon E, Valdes E, et al. Role of the glucose tolerance test as a predictor of preeclampsia. Gynecol Obstet Invest. 2014;78:130-135. doi: 10.1159/000358876.

10. Yu CK, Smith GC, Papageorghiou AT, Cacho AM, Nicolaides KH, Fetal Medicine Foundation Second Trimester Screening G. An integrated model for the prediction of preeclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. Am J Obstet Gynecol. 2005;193:429-436. doi: 10.1016/j.ajog.2004.12.014.

11. Practice ACoO. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 23, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. 2002;77:67-75. doi: 10.1016/s0020-7229(02)00002-9.

12. van Oostwaard MF, van Eerden L, de Laat MW, Duvekot J, Erwich J, Bloemennkamp K, et al. Maternal and neonatal outcomes in women with severe early onset pre-eclampsia before 26 weeks of gestation, a case series. BJOG. 2017;124:1440-1447. doi: 10.1111/1471-0728.14512.

13. Koopmans CM, van Pampus MG, Groen H, Aarnoudse JG, van den Berg PP, Mol BW. Accuracy of serum uric acid as a predictive test for maternal complications in pre-eclampsia: bivariate meta-analysis and decision analysis. Eur J Obstet Gynecol Reprod Biol. 2009;146:8-14. doi: 10.1016/j.ejogrb.2009.05.014.

14. Allen RE, Rogozinska E, Cleverly K, Aquilina J, Thangaratinam S. Abnormal blood biomarkers in early pregnancy are associated with preeclampsia: A meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2014;182:194-201. doi: 10.1016/j.ejogrb.2014.09.027.

15. Martin JN Jr., May WL, Magann EF, Terrone DA, Rinehart BK, Blake PC. Early risk assessment of severe preeclampsia: admission battery of symptoms and laboratory tests to predict likelihood of subsequent significant maternal morbidity. Am J Obstet Gynecol. 1999;180:1407-1414. doi: 10.1006/ajog.1999.5022-8.

16. Salako BL, Odukogbe AT, Olayemi O, Adedapo KS, Aimakhu CO, Alu FE, et al. Serum albumin, creatinine, uric acid and hypertensive disorders of pregnancy. East Afr Med J. 2003;80:424-428.

17. Manjareeka M, Nanda S. Elevated levels of serum uric acid, creatinine or urea in preeclamptic women. Int J Med Sci Public Health. 2013;2:43-47. doi: 10.5455/jmsph.2013.2.43-47.

18. Bainbridge SA, Roberts JM. Uric acid as a pathogenic factor in preeclampsia. Placenta. 2008;29(supplA:S67-72. doi: 10.1016/j.placenta.2007.11.001.

19. Roberts JM, Bodnar LM, Lain KY, Hubel CA, Markovic N, Ness RB, et al. Uric acid is as important as proteinuria in identifying fetal risk in women with gestational hypertension. Hypertension. 2005;46:1263-1269. doi: 10.1161/01.HYP.0000188703.27002.14.

20. Thangaratinam S, Ismail KM, Sharp S, Coomarasamy A, Khan KS. Tests in Prediction of Pre-eclampsia/Sever. Accuracy of serum uric acid in predicting complications of pre-eclampsia: a systematic review. BJOG.2006;113:369-378. doi: 10.1111/j.1471-0528.2006.00908.x.

21. Williams KP, Galerneau F. The role of serum uric acid as a prognostic indicator of the severity of maternal and fetal complications in hypertensive pregnancies. J Obstet Gynaecol Can. 2002;24:628-632. doi: 10.1016/s1701-2163(16)30193-1.

22. Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2005;52:283-289.doi: 10.1002/art.20761.

23. Li S, Sanna S, Maschio A, Busonero F, Usala G, Mulas A, et al. The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genetics.2007;3:e194. doi: 10.1371/journal.pgen.0030194.

24. Burwick RM, Feinberg BB. Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta. 2013;34:201-203. doi: 10.1016/j.placenta.2012.11.014.

25. Thangaratinam S, Koopmans CM, Iyengar S, Zamora J, Ismail KM, Mol BW, et al. Accuracy of liver function tests for predicting adverse maternal and fetal outcomes in women with preeclampsia: a systematic review. Acta Obstet Gynecol Scand. 2011;90:574-585. doi: 10.1111/j.1600-0412.2011.01112.x.

26. Demirci SC, Evrucu C, Ozgunen FT, Urunasik IF, Candan E, Kadayifci O. Factors that influence morbidity and mortality in severe preeclampsia, eclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome. Saudi Med J. 2006;27:1015-1058.

27. Hall DR, Ondendaal HJ, Kirsten GF, Smith J, Grove D. Expectant management of early onset, severe pre-eclampsia: perinatal outcome. BJOG. 2008;115:1258-1264.

28. Qublan HS, Ammarin V, Bataineh O, Al-Shraideh Z, Tahat Y, Awamleh I, et al. Lactic dehydrogenase as a biochemical marker of adverse pregnancy outcome in severe pre-eclampsia. Med Sci Monit. 2005;11:CR393-CR397.

29. Peralta Pedrero ML, Basavilvazo Rodriguez MA, Cruz Avelar A, Sanchez Ambriz S, Guzman Ibarra Mde L, Martinez Garcia Mde C. [Clinical significance of the laboratory determinations in preeclamptic patients]. Ginecol Obstet Mex. 2004;72:37-62.

Author's Contribution:

MK: Conception and study design, Final approval of the version to be published.
NA: Data collection, study design, manuscript editing and approval.
HV: Revising the article critically for important intellectual content.
TZ: Acquisition of data, Drafting the article.
HRS: Data analysis & interpretation of data.
KB: Acquisition of data, & interpretation of data.